Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients
1. TRVI’s Phase 2b CORAL trial showed significant cough reduction with Haduvio. 2. Top-line results revealed reductions of 60.2%, 53.4%, and 47.9% versus placebo. 3. 65% of patients showed 50% cough reduction using 108 mg BID Haduvio. 4. Statistically significant results were observed in multiple secondary endpoints. 5. Stock declined by 10.45% at $5.83 despite positive data release.